TY  - JOUR
A1  - Miethke, Marcus
A1  - Pieroni, Marco
A1  - Weber, Karl Tilmann
A1  - Brönstrup, Mark
A1  - Hammann, Peter
A1  - Halby, Ludovic
A1  - Arimondo, Paola B.
A1  - Glaser, Philippe
A1  - Aigle, Bertrand
A1  - Bode, Helge Björn
A1  - Moreira, Rui
A1  - Li, Yanyan
A1  - Luzhetskyy, Andriy
A1  - Medema, Marnix H.
A1  - Pernodet, Jean-Luc
A1  - Stadler, Marc
A1  - Tormo, José Rubén
A1  - Genilloud, Olga
A1  - Truman, Andrew W.
A1  - Weissman, Kira J.
A1  - Takano, Eriko
A1  - Sabatini, Stefano
A1  - Stegmann, Evi
A1  - Brötz, Heike
A1  - Wohlleben, Wolfgang
A1  - Seemann, Myriam
A1  - Empting, Martin
A1  - Hirsch, Anna K. H.
A1  - Loretz, Brigitta
A1  - Lehr, Claus-Michael
A1  - Titz, Alexander
A1  - Herrmann, Jennifer
A1  - Jäger, Timo
A1  - Alt, Silke
A1  - Hesterkamp, Thomas
A1  - Winterhalter, Mathias
A1  - Schiefer, Andrea
A1  - Pfarr, Kenneth
A1  - Hoerauf, Achim
A1  - Graz, Heather
A1  - Graz, Michael
A1  - Lindvall, Mika
A1  - Ramurthy, Savithri
A1  - Karlén, Anders
A1  - Dongen, Maarten van
A1  - Petkovic, Hrvoje
A1  - Keller, Andreas
A1  - Peyrane, Frédéric
A1  - Donadio, Stefano
A1  - Fraisse, Laurent
A1  - Piddock, Laura J. V.
A1  - Gilbert, Ian H.
A1  - Moser, Heinz E.
A1  - Müller, Rolf
T1  - Towards the sustainable discovery and development of new antibiotics
T2  - Nature reviews. Chemistry
N2  - An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in their development, particularly in the fields of natural-product-derived and synthetic small molecules. New agents displaying innovative chemistry and modes of action are desperately needed worldwide to tackle the public health menace posed by antimicrobial resistance. Here, our consortium presents a strategic blueprint to substantially improve our ability to discover and develop new antibiotics. We propose both short-term and long-term solutions to overcome the most urgent limitations in the various sectors of research and funding, aiming to bridge the gap between academic, industrial and political stakeholders, and to unite interdisciplinary expertise in order to efficiently fuel the translational pipeline for the benefit of future generations.
KW  - Business strategy in drug development
KW  - Drug therapy
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63254
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-632543
SN  - 2397-3358
N1  - Coordination of the IRAADD consortium is funded by the JPIAMR-VRI, including the publication of this article. The project on PqsR pathoblocker development acknowledges funding through the German Center for Infection Research (DZIF; projects TTU09.908 and TTU09.916), the Helmholtz Association (Helmholtz Validation Fund) and additional contributions by the associated academic institutes (HZI and HIPS). The development of chelocardins is supported by the DZIF (TTU09.814/09.821), the Helmholtz Innovation Fund (Pre-4D), by the Slovenian Research Agency, ARRS, grant no. J4-8226, and in collaboration with AciesBio, Slovenia. The corallopyronin project is funded by the DZIF (TTU09.807/09.816, TTU09.914), the German Federal Ministry of Education and Research (BMBF), the federal state of North Rhine-Westphalia (EFRE.NRW) and EU Horizon 2020. Eriko Takano was funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 720793 “TOPCAPI: Thoroughly Optimised Production Chassis for Advanced Pharmaceutical Ingredients”.
VL  - 5
SP  - 726
EP  - 749
PB  - Macmillan Publishers Limited, part of Springer Nature
CY  - Basingstoke
ER  -